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any of three evaluated antibiotic. The use of resources as estimated according to 
Mexican Social Security Institutions expenses and its use were simulated within a 
decision tree with Bayesian approach. The model considered clinical success as the
best health state, reached in either short hospital stay or long hospital stay and a 
therapeutic failure of ﬁ rst-line antibiotic therapy (DAP, VAN or LIN) which caused 
the use of a second-line antibiotic therapy (DAP or LIN depending on ﬁ rst election). 
Costs calculation considered hospital stay, concomitant medication and selected anti-
biotic treatment. Results were evaluated with incremental analysis and one-way sen-
sitivity analysis of the most uncertain variables were also conducted. RESULTS: The
use of i.v. Daptomycin as ﬁ rst-line therapy followed by i.v. Linezolid in case of thera-
peutic failure resulted in the lowest total cost per clinical success (DAP-LIN: $3255.00 
USD/CS; VAN-DAP: $3310.00 USD/CS; VAN-LIN: $3310.00 USD/CS; LIN-DAP: 
$3423.00 USD), attaining a 98% of CS. The sensitivity analysis varying clinical success 
rates of every evaluated alternative showed robustness of base study. CONCLU-
SIONS: Daptomycin is the most cost-effective alternative in the treatment of CSSI 
when used as ﬁ rst-line antibiotic therapy since its use reduces the length of hospital 
stay reducing expenses of public health system budget in Mexico.
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OBJECTIVES: To determine the most cost-effective antibiotic treatment for compli-
cated skin and skin-structure infections (CSSI) in public health care institutions in 
Mexico. METHODS: A cost-effectiveness study with institutional perspective was 
conducted comparing the use of either i.v. Daptomycin (DAP), i.v. Vancomycin (VAN) 
or i.v. Linezolid (LIN) as ﬁ rst-line antibiotic therapy. Data collection obtained with a
systematic review considered efﬁ cacies measured as clinical improvement, length of 
stay at hospital services and adverse events. A decision tree with Bayesian approach
was designed to simulate the use of resources based on patient’s prognosis due to use 
one of the evaluated alternatives. Patients are supposed to reach either of two different 
health states: clinical success and therapeutic failure, the former can be attained 
through a short hospital stay or a long hospital stay depending on selected treatment, 
the latter requires the administration of a second-line antibiotic therapy increasing 
cost. Costs calculation considered hospital stay, concomitant medication and selected
antibiotic treatment. Results were evaluated with incremental analysis and one-way 
sensitivity analysis of the most uncertain variables were also conducted. RESULTS:
The use of i.v. Daptomycin results in the lowest total cost (DAP: $3,078.00 USD; 
VAN: $3,159.00 USD; LIN: $3,173.USD) and the lowest cost per clinical success (CS) 
(DAP: $3,405.00 USD/CS; VAN:$3,550.00 USD/CS; LIN:$3,870.00 USD/CS) com-
pared with i.v. Vancomycin or i.v. Linezolid. The sensitivity analysis varying clinical 
success rates of every evaluated alternative showed robustness of base study. CON-
CLUSIONS: Daptomycin is the most cost-effective alternative in the treatment of CSSI 
when used as ﬁ rst-line antibiotic therapy since its use reduces the length of hospital 
stay reducing expenses of public health system budget in Mexico.
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OBJECTIVES: Acute otitis media (AOM) is a prevalent pediatric condition, affecting
approximately 80% of children by three years of age. Routine immunization programs 
include 7-valent Pneumococcal conjugate vaccine (PCV-7), associated with a reduction
of AOM events caused by Streptococcus pneumoniae. The objective of this study was
to compare the costs and effects of PCV-7 with PHiD-CV, a newly approved in Canada
Pneumococcal non-typeable Haemophilus inﬂ uenzae Protein D-conjugate vaccine 
employing an active protein D-carrier associated with reduction of nontypeable Hae-
mophilus Inﬂ uenzae (NTHi) AOM. METHODS: A steady-state, population-based 
model with a one-year time horizon was developed, and calibrated with Canadian
epidemiologic and demographic data, to investigate the costs and effects associated 
with AOM episodes across the Canadian population. A 4-dose schedule for PHiD-CV 
vaccination was compared with a 4-dose schedule for PCV-7 vaccination. The base-
case included herd-protection for invasive pneumococcal disease and serotype 6A cross
protection. A health care system perspective was taken with the assumption of 100% 
vaccination coverage. RESULTS: Compared with PCV-7, vaccination with PHiD-CV 
could prevent an additional 170,951 ambulatory visits for AOM, 144,454 antibiotic 
prescriptions for AOM, and 9,830 hospitalizations for myringotomy per year. With 
PCV-7 the total direct costs associated with AOM are $119.8 million of which $16.9
million could be off-set by implementation of routine vaccination with PHiD-CV.
CONCLUSIONS: Based on the base-case analysis, inclusion of PHiD-CV in routine
immunization programs across Canada would be cost-saving to the health care system
compared with PCV-7. PHiD-CV offers substantial beneﬁ ts in terms of reduced ambu-
latory visits, antibiotic prescriptions and hospitalizations for AOM, a highly prevalent 
childhood condition.
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OBJECTIVES: Psoriasis is a chronic debilitating immune-mediated inﬂ ammatory
disease, with no cure, affecting an estimated one million Canadians. Studies show that
up to 85% of psoriasis is of plaque type and up to 25% of sufferers have either moder-
ate or severe disease. There are no reliable estimates of the economic burden of pso-
riasis in Canada. The objective is to estimate the economic burden of moderate to
severe chronic plaque psoriasis in Canada in 2008, inclusive of direct medical and
non-medical, and lost productivity costs. METHODS: Using a cross-sectional design, 
data were collected on 90 patients diagnosed with moderate or severe chronic plaque 
psoriasis in three dermatology clinics (British Columbia, Ontario, and Quebec). Data
were obtained from three sources: clinic charts determining medical resources utilized 
for treatment; patient questionnaires eliciting information on non-medical resources
utilized, lost productivity, and the impact on quality of life (QoL) using the Dermatol-
ogy Quality of Life Index (DLQI); and unit costs (all in CDN$2008) from published
sources. RESULTS: The estimated mean annual costs of treating patients with moder-
ate to severe chronic plaque psoriasis was $7966/patient, of which $4524 (95% con-
ﬁ dence interval (CI): $2246 to $6802) was due to direct medical and non-medical
costs, and $3442 (95% CI: $1293 to $5590) was due to lost productivity. The esti-
mated mean DLQI of 6.7 is reﬂ ective of a moderate impact on QoL in moderate to
severe psoriasis patients. CONCLUSIONS: Extrapolating these costs to the estimated 
number of affected Canadians means that moderate to severe psoriasis costs on the
order of $961.3 million (95% CI: $477.3 million to $1.4 billion) in direct medical 
and non-medical costs annually. The total cost to society is approximately $1.7 billion
(95% CI: $752.0 million to $2.6 billion). This economic burden coupled with the
QoL effect indicates the need for more efﬁ cient and long-term control.
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OBJECTIVES: Severe Chronic Hand Eczema (CHE) or Chronic Hand Dermatitis
(CHD), is characterized by thick scaly skin causing painful ﬁ ssures, erythema, itching, 
blustering and oedema. Severe CHE/CHD is often unresponsive to conventional 
topical corticosteroids and results in substantial occupational, personal, and psycho-
logical disability. There is currently a lack of information regarding the economic
burden of CHE/CHD in Canada. METHODS: A dynamic Excel model was devel-
oped to estimate the cost of treating adults with severe CHE in Canada. Epidemiologi-
cal/clinical data were derived from systematic literature searches. A Delphi panel of 
dermatologists provided estimates of resource utilization and validated epidemiologi-
cal/clinical rates. Given the impact on lost productivity, a pseudo societal perspective 
was chosen; out of pocket expenses (travel and non-prescription pharmacotherapies)
were excluded from the analysis. Unit costs were derived from Ontario standard lists
and reported as 2008 Canadian dollars. RESULTS: In 2008 the estimated adult popu-
lation was 26 million. From the literature it was determined that 10% of adults may 
be affected by CHE, of those 6.7% may have severe CHE/CHD. Asscessing 50% of 
these patients don’t adequately respond to topical corticosteroids, an estimated 87,200 
Canadians have severe CHE being refractory to topicals. Treatment costs, including 
lost productivity, was calculated to be $737 million per annum. Even assuming current 
second-line treatment options are 100% effective, the cost of severe CHE was esti-
mated to be $390 million per annum. CONCLUSIONS: This study estimated the costs 
of severe CHE/CHD unresponsive to topical corticosteroids in Canada ranges from 
$390–$737 million per annum. The majority of costs comes from lost productivity
due to disease and accessing treatment.
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OBJECTIVES: The purpose of this study was to assess the cost-utility of posterior
lamellar keratoplasty techniques, including deep lamellar endothelial keratoplasty 
(DLEK), Descemet stripping endothelial keratoplasty (DSEK) and Descemet stripping
automated endothelial keratoplasty (DSAEK), in the treatment of corneal endothelial 
diseases. METHODS: This cost-utility analysis was performed from a Canadian health
system perspective over a lifetime period. A Markov model was constructed to 
compare the cost per quality adjusted life year (QALY) associated to penetrating kera-
toplasty (PK) and lamellar keratoplasty techniques (DLEK, DSEK and DSAEK). The 
Markov model included all major health states relevant to patients scheduled for
corneal transplantation: waiting for transplantation, surviving graft with or without 
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complications, irreversible failure, non-eligibility and death. Transition probabilities 
between health states were obtained from results of published clinical trials. Costs 
included in the model comprised those associated with surgery, patients’ follow up
and post-surgical complications. Speciﬁ cally, costs related to visits to physician, medi-
cations as well as those incurred at the hospital were included in the model. Number 
of QALYs was estimated pre and post-surgery using the EQ-5D questionnaire from
patients undergoing PK or lamellar surgery at Maisonneuve Rosemont Hospital (Mon-
treal, Qc). RESULTS: The lamellar keratoplasty techniques were proved to be more 
effective, providing more QALYs (43 QALYs / 100 patients), and were less costly 
(50,437 CD$ / 100 patients) compared to PK. The gain of QALYs associated with 
lamellar keratoplasty resulted from a reduction of the waiting time for transplantation 
and from lower postoperative complication rates, both related to poor utility values. 
Deterministic and probabilistic sensitivity analyses conﬁ rmed the robustness of the
base-case results. CONCLUSIONS: From a clinical and an economic standpoint, 
lamellar keratoplasty represents a preferred strategy for the treatment of corneal 
endothelial diseases.
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OBJECTIVES: Implantation of toric intraocular lens (IOL) corrects preexisting astig-
matism in cataract patients, providing better clinical outcomes compared to conven-
tional monofocal IOLs. We sought to assess the impact of these clinical outcomes on 
lifetime patient health-related quality of life (HRQL) and economic outcomes.
METHODS: A clinically based economic model examined outcomes in cataract 
patients q 65 years old with pre-existing astigmatism (1.5–3D). Subjects received either
bilateral toric IOLs or conventional IOLs, with or without intra-operative refractive 
correction for astigmatism. Data obtained from a systematic literature review were
supplemented with survey results from 60 United States cataract and refractive sur-
geons. A prospective study provided data translating uncorrected visual acuity (UCVA) 
to patient utilities. Outcomes were projected over life time and discounted at 3%.
RESULTS: The proportion of patients achieving spectacle independence and UCVA q
20/25 with toric IOL was greater (67% and 53%) than that with conventional IOL
with (63% and 48%) or without (53% and 44%) intra-operative refractive correction.
Due to better UCVA outcomes, Toric IOL resulted in better utility scores than con-
ventional IOL with and without intra-operative refractive correction. This utility gain,
coupled with a reduced lifetime likelihood of wearing glasses and contact lenses
resulted in toric IOL being the dominant strategy over conventional IOL without
intra-operative refractive correction. The use of toric IOL resulted in the total lifetime
cost saving of $336/QALY. CONCLUSIONS: Toric IOLs improve patients’ HRQL
by providing better vision outcomes and reduction in the need for intra- and post-
operative refractive correction in cataract patients with astigmatism thus reducing the 
risks associated with refractive surgery. Other than visual acuity, additional factors 
should be considered by physicians and patients for the initial choice of treatment: 
the inconvenience of travel with glasses, lens cleaning and intangible beneﬁ ts associ-
ated with improved self-perception.
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OBJECTIVES: Burn patients undergoing skin graft ﬁ xation utilize additional health
care resources with removal of staples (RoS). The objective of this study was to report
time and resources utilized during RoS. METHODS: Data were extracted from a
phase three multi-center clinical trial assessing efﬁ cacy and safety of a ﬁ brin sealant 
(FS) compared to staples. Subjects had burn wounds measuring 40% of total body
surface area (TBSA) and study wound sites measured 1–4% of TBSA. Health resource
assessment included number of staples, number of visits to remove staples, time to
remove staples, number of health care personnel removing staples, and additional pain 
medication. RESULTS: A total of 127 patients were included in this analysis. Of those,
66% were male and 69% were white. The median age was 29 years (range 1–62 
years). The median number of staples used for skin grafting was 30 (range 7–88). One
visit was required (Range 1–2), utilizing 10 minutes (Range 1–365) to remove staples.
A median of 2 health care professionals were involved (range 1–9). A total of 59%
of patients received additional sedation/pain medication during staple removal. The
mean number of medications administered was 1.4 (range 1–3), and the most common
choices were midazolam  fentanyl, morphine, or ketamine. CONCLUSIONS:
Removal of staples requires additional medical resources that can be quantiﬁ ed in 
terms of costs. Comprehensive cost-beneﬁ t analyses are needed to compare total cost
of care by method of graft ﬁ xation.
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OBJECTIVES: Long-term treatment with 0.1% tacrolimus ointment (TO) has been 
demonstrated as well-tolerated and effective for the treatment of atopic dermatitis (AD)
but its impact on utility has not been reported. The purpose of this study was to esti-
mate utility changes associated with TO versus a standard corticosteroid regimen (CR)
in the treatment of moderate-to-severe AD in adults. METHODS: Data were analysed 
from a double-blind RCT. Patients were treated with either TO applied twice-daily for 
six months to the head, neck, trunk and extremities, or alternatively 0.1% hydrocorti-
sone butyrate ointment administered to the trunk and extremities and 1% hydrocorti-
sone acetate ointment applied to the head and neck. Health-related utility (EQ5Dindex)
was estimated by Monte Carlo simulation from SF12 responses collected during the 
clinical trial by applying a published mapping algorithm. RESULTS: Data were avail-
able for 972 patients (intention-to-treat), 46% of whom were male with a mean age of 
32 years (SD 12). At baseline the mean EQ5Dindex was similar between both arms 
(0.721 vs. 0.730; p  0.461, for CR vs. TO, respectively). After 28 days the mean
EQ5Dindex improved in both treatment arms (0.820 vs. 0.849; p  0.004, respectively).
The incremental EQ5Dindex between the treatment arms increased as the trial pro-
gressed. At 6-months subjects treated with TO had signiﬁ cantly higher utility than 
CR-treated subjects (0.789 vs. 0.831; p  0.001; respectively). CONCLUSIONS:
Patients with AD had considerable decrement in health-related utility at baseline. Treat-
ment with 0.1% tacrolimus ointment was associated with a consistently improved, 
clinically-signiﬁ cant, incremental increase in health-related utility compared to the 
corticosteroid regimen, increasing over a six month period.
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OBJECTIVES: Progressive vision loss caused by retinopathy is a common and debili-
tating effect of diabetes. Standardized descriptions of the functional impacts of diabetic 
retinopathy are required to develop health state descriptions for eliciting utilities. The
objective was to characterize the functional impacts of diabetic retinopathy according
to levels of visual function, informing relevant health states in diabetic retinopathy.
METHODS: A list of potentially important impacts was developed from the literature
and the National Eye Institute Visual Function Questionnaire (VFQ). One-on-one 
qualitative interviews were then conducted with 30 subjects with diabetic retinopathy 
to solicit feedback on functional and activity limitations. All participants underwent 
Early Treatment of Diabetic Retinopathy Study visual acuity and contrast sensitivity 
testing. A thematic analysis characterized the nature and drivers of functional limita-
tions in diabetic retinopathy. Health state descriptions using these parameters were 
developed and reviewed by three ophthalmologists and one endocrinologist. RESULTS:
Qualitative interviewing identiﬁ ed that visual acuity and contrast sensitivity in the 
better- and worse-seeing eyes, the difference in these measures between the eyes, and
the ability to drive were important determinants of health status. These status indica-
tors were highly associated with participation in leisure activities; reading ﬁ ne print 
(important for maintaining glycemic control when reading nutritional labels or glu-
cometers); seeing well at a distance; and mobility outside the home. Functional limita-
tions less useful in distinguishing between individuals with different visual functioning
levels included watching television and needing help from others. Eleven unique health 
states, deﬁ ned by visual acuity, contrast sensitivity, and VFQ scores, were then devel-
oped which can be used for estimating vision-related utilities in diabetic retinopathy. 
CONCLUSIONS: This is the ﬁ rst study to categorize the vision-speciﬁ c functional
impacts of diabetic retinopathy according to measures of vision function. Measuring
health state utilities for diabetic retinopathy is now feasible using these health state 
descriptions.
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OBJECTIVES: To explore how driving status and bilateral visual acuity (best-eye 
(BEVA) and worst-eye (WEVA)) impact quality of life (QOL) in patients with NV-
ARMD in terms of health utility (HU) derived from the EuroQol (EQ-5D) and QOL
derived from the National Eye Institute Vision Function Questionnaire (NEI-VFQ 25).
METHODS: This cross-sectional data (n  154) at screening from a phase I/II clinical 
trial in patients with NV-ARMD was conducted in 4 countries. Patients were stratiﬁ ed 
into 4 severity groups (BEVA, 20/40; WEVA, 20/200). Four driving statuses were
extracted from NEI-VFQ 25 questions 15a and 15b, including current drivers (D),
